Clinical Research Directory

Inclusion Criteria: * Aged 18-70 years, with no restriction on gender. * Meeting the Rome V diagnostic criteria for IBS-C. * Stable constipation phenotype during the screening period; participants are expected to have fewer than 3 CSBMs per week, or be judged by the investigator to present constipation features consistent with IBS-C. * IBS-SSS score ≥ 175, indicating at least moderate IBS symptoms. * HADS-A score ≥ 8, indicating the presence of anxiety status. * Stable regimens of IBS-related medications, anxiolytic/antidepressant agents and other treatments that may affect gastrointestinal motility for at least 2 weeks prior to enrollment; participants are willing to avoid adding relevant new treatments during the study period. * Able to understand study procedures and willing to complete acupuncture treatment, home-based TEA/sham-TEA therapy, symptom diaries and follow-up assessments. * Voluntarily participate in the study and provide written informed consent. Exclusion Criteria: * Presence of organic diseases that could account for symptoms, including inflammatory bowel disease, colorectal neoplasm, intestinal obstruction, coeliac disease, uncontrolled thyroid disease, and diabetic autonomic neuropathy. * Presence of alarm features such as hematochezia, unexplained weight loss, anemia, fever, nocturnal symptoms, and family history of colorectal cancer without completion of necessary diagnostic work-up. * Previous major abdominal surgery that may significantly impair intestinal function. * Severe mental disorders, bipolar disorder, psychotic symptoms, substance dependence, significant suicide risk, or conditions requiring immediate psychiatric intervention. * New initiation or dose adjustment of anxiolytics, antidepressants, antipsychotics, opioids, strong anticholinergic agents, prokinetics, or regular laxatives within 4 weeks prior to screening. * Implanted cardiac pacemaker, implantable cardioverter-defibrillator or other implanted electronic devices, or presence of unstable arrhythmia. * Skin breakdown, infection, severe skin disease at TEA electrode sites, or allergy to electrode materials. * Contraindications to acupuncture, such as severe coagulopathy, inability to tolerate acupuncture, or extremely high risk of acupuncture syncope. * Pregnancy, lactation, or planned pregnancy during the study period. * Participation in another interventional clinical trial within the past 3 months. * Other conditions judged by the investigator to render the participant unsuitable for this study.